Kisqali (ribociclib) and Kisqali Femara Co-Pack coverage
Customize your policy alerts
Sign up for all medical mutual - ohio policy alerts
Know when medical mutual - ohio releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization, clinical coverage criteria, and approval durations for Kisqali (ribociclib) alone or as a co-pack with letrozole for treating HR+, HER2- advanced or high-risk early breast cancer in adults; applies to Medical Mutual - Ohio pharmacy benefit reviews.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Medical necessity criteria
Coverage is recommended when ALL of the following criteria are met for the specified populations:
High risk of recurrence includes any lymph node involvement; tumor size > 5 cm; or tumor size 2–5 cm with either grade 2 (and high genomic risk or Ki‑67 ≥ 20%) or grade 3 disease.
Premenopausal/perimenopausal patients must receive ovarian suppression/ablation (examples: leuprolide, triptorelin, goserelin).
Men receiving an aromatase inhibitor must receive concomitant GnRH agonist for testicular suppression (examples: leuprolide, triptorelin, goserelin).
Prescriber must provide specific diagnosis documentation.
Initial approval duration: 6 months; extended approval duration: 1 year.
Uses not listed in this policy will be reviewed on a case-by-case basis and require submission of supporting evidence for efficacy and medical necessity. Such requests may be considered investigational or not recommended for approval unless the reviewer determines there is sufficient clinical evidence and documented need to support coverage.
Therapy may be denied if the drug or service is determined to be investigational/experimental or not medically necessary following review. The Company may also deny reimbursement if the treatment is not within the member’s scope of benefits or if inappropriate or excessive billing or practice patterns are identified. The Company reserves the right to modify, revise, change, apply, and interpret this policy at its sole discretion.
| Regimen | Indication / line of therapy | Coverage status |
|---|---|---|
| Ribociclib in combination with anastrozole | ||
| HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy (postmenopausal or premenopausal with ovarian suppression) | ||
| Ribociclib in combination with exemestane | ||
| HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy (postmenopausal or premenopausal with ovarian suppression) | ||
| Ribociclib in combination with letrozole | ||
| HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy (postmenopausal or premenopausal with ovarian suppression) | ||
| Ribociclib in combination with fulvestrant | ||
| HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy or second‑line/subsequent therapy with fulvestrant only if no prior CDK4/6 inhibitor exposure (postmenopausal or premenopausal with ovarian suppression) | ||
| Kisqali Femara Co‑Pack (ribociclib + letrozole) | ||
| HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy (postmenopausal or premenopausal with ovarian suppression) | ||
Prior Authorization Codes and Biomarker Thresholds
| affected codes | placeholder for pharmacy benefit codes referenced by payer |
Prior Authorization, Prescriber Requirements, and Documentation
Prior Authorization Recommended
Prior authorization is recommended for pharmacy benefit coverage of Kisqali/Kisqali Femara Co-Pack. Initial prescribing must be by or in consultation with a physician who specializes in the condition being treated; specifically, the drug must be prescribed by or in consultation with a hematologist or oncologist for initial therapy. All approvals for initial therapy are provided for the initial approval duration noted in the policy.
- Prior authorization recommended for pharmacy benefit
- Initial prescriber: hematologist or oncologist (or in consultation with one)
- Initial approvals provided for the initial approval duration specified in the policy
Line of Therapy Constraints
Line of therapy constraints apply based on prior exposure to CDK4/6 inhibitors and menopausal status. For postmenopausal patients, Kisqali may be used as first-line endocrine therapy in combination with anastrozole, exemestane, letrozole, or fulvestrant, or as first-line when using the Kisqali Femara Co-Pack. Kisqali may be used as second-line or subsequent endocrine therapy in combination with fulvestrant only if a CDK4/6 inhibitor has not been used previously. For premenopausal or perimenopausal patients receiving ovarian suppression/ablation, the same first-line and restricted second-line rules apply. Equivalent line-of-therapy rules apply for men meeting criteria, with concomitant GnRH agonist when combined with an aromatase inhibitor.
- First-line use: Kisqali + aromatase inhibitor or fulvestrant, or Kisqali Femara Co-Pack as first-line
- Second-line/subsequent use with fulvestrant only if no prior CDK4/6 inhibitor exposure
- Premenopausal/perimenopausal patients must have ovarian suppression/ablation when applicable
- Men: follow similar first-/second-line rules; use GnRH agonist when combined with an aromatase inhibitor
Supporting Documentation and Denial Triggers
The Company may request additional documentation to support medical necessity. Documentation may include patient medical records, diagnostic test results, and provider credentials. Failure to provide requested documentation may result in denial of coverage. The Company may also deny reimbursement if the drug or service is deemed not medically necessary, investigational/experimental, outside the member's benefit scope, or if there is a pattern of inappropriate or excessive billing.
- Company may request patient records, test results, and provider credentials
- Additional documentation must be made available upon request to support medical necessity
- Denial triggers include: not medically necessary, investigational/experimental, outside scope of benefits, or inappropriate/excessive billing patterns
Definitions and Risk Stratification
Line of Therapy Criteria
Line of therapy — first-line | second-line
Different rules apply by patient group: premenopausal/perimenopausal patients require ovarian suppression/ablation; men require concomitant GnRH agonist when receiving an aromatase inhibitor.
Hormone Receptor and HER2 Status; Proliferation Index
Clinical Background
Ribociclib is a cyclin-dependent kinase (CDK4/6) inhibitor that prevents phosphorylation of the retinoblastoma protein (Rb), producing G1 cell-cycle arrest and decreased cellular proliferation in estrogen receptor–positive (ER+) breast cancer. It is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for appropriate patients and is available as single-agent tablets or co‑packaged with letrozole.
Policy Revision History
Annual review completed; policy last revised and reviewed on 02/19/2026.
Initial and extended approval durations defined (initial 6 months; extended 1 year).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.